Shares of Acceleron Pharma Inc (NASDAQ:XLRN) have earned a consensus recommendation of “Buy” from the nineteen research firms that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $49.33.
XLRN has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $62.00 target price on shares of Acceleron Pharma in a research note on Wednesday, February 28th. Credit Suisse Group set a $51.00 target price on Acceleron Pharma and gave the stock a “buy” rating in a research note on Tuesday, November 14th. BidaskClub raised Acceleron Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, February 15th. Oppenheimer reissued a “hold” rating on shares of Acceleron Pharma in a research note on Monday, December 11th. Finally, Cann reissued a “hold” rating on shares of Acceleron Pharma in a research note on Monday, January 8th.
Acceleron Pharma (XLRN) traded down $0.70 during mid-day trading on Friday, reaching $43.88. The company’s stock had a trading volume of 44,893 shares, compared to its average volume of 313,799. The firm has a market capitalization of $2,018.88, a PE ratio of -16.53 and a beta of 1.39. Acceleron Pharma has a one year low of $24.37 and a one year high of $46.93.
Acceleron Pharma (NASDAQ:XLRN) last posted its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.02). The business had revenue of $3.71 million for the quarter, compared to analyst estimates of $3.39 million. Acceleron Pharma had a negative return on equity of 38.71% and a negative net margin of 804.49%. research analysts anticipate that Acceleron Pharma will post -2.5 EPS for the current fiscal year.
In other news, SVP Christopher Rovaldi sold 2,266 shares of Acceleron Pharma stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $42.42, for a total value of $96,123.72. Following the completion of the sale, the senior vice president now directly owns 52,977 shares of the company’s stock, valued at $2,247,284.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jean George sold 105,122 shares of Acceleron Pharma stock in a transaction on Friday, December 15th. The shares were sold at an average price of $35.73, for a total value of $3,756,009.06. Following the completion of the sale, the director now directly owns 1,250 shares of the company’s stock, valued at $44,662.50. The disclosure for this sale can be found here. Insiders sold 183,521 shares of company stock valued at $7,082,848 over the last ninety days. Insiders own 3.90% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Parametric Portfolio Associates LLC grew its stake in shares of Acceleron Pharma by 3.9% in the second quarter. Parametric Portfolio Associates LLC now owns 9,456 shares of the biopharmaceutical company’s stock valued at $287,000 after buying an additional 355 shares in the last quarter. California Public Employees Retirement System boosted its holdings in Acceleron Pharma by 6.7% in the fourth quarter. California Public Employees Retirement System now owns 22,300 shares of the biopharmaceutical company’s stock valued at $946,000 after purchasing an additional 1,400 shares during the period. American International Group Inc. boosted its holdings in Acceleron Pharma by 8.1% in the third quarter. American International Group Inc. now owns 21,487 shares of the biopharmaceutical company’s stock valued at $802,000 after purchasing an additional 1,607 shares during the period. Quantbot Technologies LP boosted its holdings in Acceleron Pharma by 416.3% in the third quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 2,352 shares during the period. Finally, California State Teachers Retirement System boosted its holdings in Acceleron Pharma by 5.2% in the second quarter. California State Teachers Retirement System now owns 56,795 shares of the biopharmaceutical company’s stock valued at $1,726,000 after purchasing an additional 2,826 shares during the period. 88.21% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://ledgergazette.com/2018/03/14/acceleron-pharma-inc-xlrn-receives-49-33-consensus-price-target-from-analysts.html.
About Acceleron Pharma
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.